Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1805 results
February 2021
-
Media ReleaseNovartis strengthens Oncology pipeline with successful closing of tislelizumab in-licensingAdds tislelizumab, a uniquely designed anti-PD-1 monoclonal antibody for monotherapy and proprietary combination cancer therapies with Novartis portfolio and pipeline therapies Novartis will co-…
-
Media ReleaseNovartis Cosentyx® gains EU label update for first-of-its-kind MAXIMISE data in axial manifestations of psoriatic arthritisCosentyx® (secukinumab) is the first biologic with proven efficacy in all 6 key manifestations of psoriatic arthritis (PsA), and the only biologic with fast and lasting relief of axial manifestations…
-
Media ReleaseNovartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell diseaseProject brings together Novartis drug discovery and gene therapy expertise and funding support from the Gates Foundation Agreement aims to address disparity in access to treatments and to…
-
Media ReleaseNovartis Entresto® granted expanded indication in chronic heart failure by FDAEntresto is the first and only therapy approved in the US to treat patients diagnosed with guideline-defined heart failure to include both those with heart failure with reduced ejection fraction (…
-
Key ReleaseNovartis Entresto® granted expanded indication in chronic heart failure by FDAEntresto is the first and only therapy approved in the US to treat patients diagnosed with guideline-defined heart failure to include both those with heart failure with reduced ejection fraction (…
-
Media ReleaseNovartis data show multiple sclerosis patients and nurses prefer Kesimpta® (ofatumumab) Sensoready® autoinjector penMulticenter survey results show MS patients and nurses prefer the Sensoready autoinjector pen for subcutaneous self-administration of Kesimpta over other autoinjectors for their current treatment (84…
-
Featured NewsExpanding CAR-T manufacturing in Australia
Cell Therapies Pty Ltd has become the first approved CAR-T commercial manufacturing site in Australia, providing potentially faster access to CAR-T therapies to eligible patients in the region with life-threatening blood cancers.
Novartis global commercial CAR-T manufacturing footprint now spans four continents, bringing these transformative therapies closer to patients and healthcare professionals around the world. -
Media ReleaseSandoz announces agreement to acquire GSK’s cephalosporin antibiotics business, reinforcing its leading global position in antibioticsSandoz to acquire three established brands sold in more than 100 marketsAcquisition, including leading global brand Zinnat®, confirms Sandoz commitment to antibiotics, following plans to expand its…
-
Media ReleaseNovartis receives FDA Breakthrough Therapy designations for investigational STAMP inhibitor asciminib (ABL001) in chronic myeloid leukemiaDesignation in patients with chronic myeloid leukemia (CML) resistant or intolerant to prior treatments based on positive data from pivotal Phase III ASCEMBL trial evaluating asciminib, an…
-
Featured NewsWorld Cancer Day 2021
We’re honoring World Cancer Day with a new series called “Let’s Talk About the C Word: From Cancer to Cures” to address challenging conversations on cancer.
Pagination
- ‹ Previous page
- 1
- …
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- …
- 151
- › Next page